Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

CAPD ȯÀÚ¿¡¼­ Àç¹ß¼º º¹¸·¿°ÀÇ ÀÓ»óÀû Ư¼º Clinical Characteristics of Relapsing Peritonitis in CAPD Patients

´ëÇѽÅÀåÇÐȸÁö 1997³â 16±Ç 4È£ p.738 ~ 746
¼Ò¼Ó »ó¼¼Á¤º¸
ÀÌ»óÇÐ ³ëÇöÁø/½Å¼®±Õ/ÀÌÀÎÈñ/°­½Å¿í/ÃÖ±ÔÇå/Çϼº±Ô/ÇÑ´ë¼®/ÀÌÈ£¿µ

Abstract

¿ä¾à
Áö¼Ó¼º ¿Ü·¡ º¹¸·Åõ¼®(continuous ambulatory peritoneal dialysis, ÀÌÇÏ CAPD·Î ¾àÇÔ) ½Ã
Çà½Ã ÁÖ¿ä ÇÕº´ÁõÀÇ ÇϳªÀ̸ç, CAPD Áß´ÜÀÇ ÁÖµÈ ¿øÀÎÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Â Àç¹ß¼º º¹¸·¿°Àº
Ãʱ⠺¹¸·¿°¿¡ ´ëÇÑ ºÎÀûÀýÇÑ Ä¡·á, ¹Ýº¹ÀûÀÎ Ãⱸ °¨¿°°ú ÅͳΠ°¨¿° µîÀÇ µµ°ü°ü·Ã °¨¿°
µîÀÌ ±× ¿øÀÎÀ¸·Î »ý°¢µÇ°í ÀÖÀ¸³ª, ¾ÆÁ÷ ÀÌ¿¡ ´ëÇÑ Ä¡·áÀÇ Ç¥ÁØÀº ¾ø´Â ½ÇÁ¤ÀÌ´Ù. À̶§ Àú
ÀÚ µîÀº Àç¹ß¼ºº¹¸·¿°ÀÇ ¿øÀÎ ±ÕÁÖ, Ä¡·á¾à¹° ¹× Ä¡·á±â°£¿¡ µû¸¥ Àç¹ßÀ²À» ¾Ë¾Æº¸°í, µµ°ü
Á¦°Å ¹× Àç»ðÀÔÀÇ È¿°ú¸¦ Æò°¡ÇØ º¸°íÀÚ ¿¬¼¼ÀÇ·á¿ø¿¡¼­ CAPD¸¦ ½ÃÇàÁß À̸鼭 Àç¹ß¼º º¹
¸·¿°À» °æÇèÇÑ 43¸íÀÇ È¯ÀÚ¿¡¼­ ¹ß»ýÇÑ 104¿¹ÀÇ Àç¹ß¼º º¹¸·¿°À» ´ë»óÀ¸·Î Á¶»çÇÏ¿© ´ÙÀ½°ú
°°Àº °á°ú¸¦ ¾ò¾ú´Ù.
1) 104¿¹ÀÇ Àç¹ß¼º º¹¸·¿° Áß ±ÕÁÖ°¡ Áõ¸íµÈ °æ¿ì°¡ 70¿¹(67.3%)¿´À¸¸ç, ±×Áß coagulase
negative Staphylococcus°¡ 39¿¹(39/70, 55.7%)·Î °¡Àå ¸¹¾Ò°í, Enterococcus 9¿¹(9/70,
12.9%), Staphylococcus aureus 8¿¹(8/70, 11.4%), Pseudomonas 4¿¹(4/70, 5.7%), Serratig 4
¿¹(1/70, 5.7%), Xanthomonas 3¿¹(3/70, 4.3%), Klebsiella 2¿¹(2/70, 2.9%), fungus 1 ¿¹
(1/70, 1.4%)ÀÇ ¼ø À̾ú´Ù.
2) 104¿¹ÀÇ Àç¹ß¼º º¹¸·¿°Áß µµ°üÀ» À¯ÁöÇÑ 92¿¹ Áß 46¿¹(50%)´Â ´Ù½Ã Àç¹ßÇÏ¿´°í, 46¿¹
(50%)´Â Àç¹ß ¾øÀÌ CAPD¸¦ À¯ÁöÇÏ¿´À¸¸ç, 12¿¹´Â Ä¡·á¿¡ ¹ÝÀÀÇÏÁö ¾Ê¾Æ µµ°üÀ» Á¦°ÅÇÏ¿´
´Ù. µµ°ü Á¦°Å ÈÄ 3¸íÀÇ È¯ÀÚ¿¡¼­ µµ°ü Àç»ðÀÔÀ» ½ÃµµÇÏ¿´À¸¸ç, 3¸í ¸ðµÎ¿¡¼­ ´õ ÀÌ»óÀÇ Àç
¹ßÀº ¾ø¾ú´Ù.
3) ±×¶÷¾ç¼º±Õ¿¡ ÀÇÇÑ º¹¸·¿°°ú ±×¶÷À½¼º±Õ¿¡ ÀÇÇÑ º¹¸·¿° »çÀÌ¿¡ Àç¹ßÀ²ÀÇ Â÷ÀÌ´Â ¾ø¾ú
´Ù(56 vs. 50%).
4) ù¹ø° º¹¸·¿° ½ÃÀÛ ½Ã vancomycin°ú amikacinÀ¸·Î Ä¡·áÇÑ 17¿¹Áß 5¿¹(29%),
cefazolin °ú tobramycinÀ¸·Î Ä¡·áÇÑ 30¿¹Áß 22¿¹(73%)¿¡¼­ Àç¹ßÇÏ¿©, vancomycin°ú
amikacinÀ¸·Î Ä¡ ·áÇÑ º¹¸·¿°ÀÇ °æ¿ì Àç¹ßÀ²ÀÌ À¯ÀÇÇÏ°Ô ³·¾ÒÀ¸³ª(p<0.05), ´Ù¸¥ Ç×»ýÁ¦¸¦
»ç¿ëÇß´ø º¹¸·¿° »çÀÌ¿¡´Â Àç¹ßÀ²ÀÇ Â÷ÀÌ°¡ ¾ø¾ú´Ù.
5) ÃÑ Ä¡·á±â°£ÀÌ 2ÁÖ ¹Ì¸¸À̾ú´ø ¿¹¿Í 2ÁÖ ÀÌ»óÀ̾ú´ø ¿¹¿¡¼­ Àç¹ßÀ²Àº ±×¶÷¾ç¼º±Õ¿¡ ÀÇ
ÇÑ º¹¸·¿°(63 vs. 51%)°ú ±×¶÷À½¼º±Õ¿¡ ÀÇÇÑ º¹¸·¿°(40 vs. 60%) ¸ðµÎ¿¡¼­ Â÷ÀÌ°¡ ¾ø¾úÀ¸
¸ç, coagulase negative Staphulococcus¿¡ ÀÇÇÑ º¹¸·¿°¿¡¼­´Â 2ÁÖ ÀÌ»ó Ä¡·áÇÑ °æ¿ì Àç¹ßÀ²
ÀÌ Àû¾úÀ¸³ª, °¢°¢ 59%, 30%·Î¼­ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù.
6) Áõ»óÀÇ ¼Ò½Ç ÈÄ 10ÀÏ ¹Ì¸¸µ¿¾È Ä¡·áÇÑ ¿¹¿Í 10ÀÏ ÀÌ»ó Ä¡·áÇÑ ¿¹¿¡¼­ Àç¹ßÀ²Àº ±×¶÷¾ç
¼º±Õ¿¡ ÀÇÇÑ º¹¸·¿°(59 vs. 53%)°ú ±×¶÷À½¼º±Õ¿¡ ÀÇÇÑ º¹¸·¿°(40 vs. 69%) ¸ðµÎ¿¡¼­ À¯ÀÇÇÑ
Åë°èÀû Â÷ÀÌ°¡ ¾ø¾úÀ¸¸ç, coagulase negative Staphulococcus¿¡ ÀÇÇÑ º¹¸·¿°¿¡¼­´Â Áõ»óÀÇ
¼Ò½Ç ÈÄ 10ÀÏ ÀÌ»ó Ä¡·áÇÑ ¿¹¿¡¼­ Àç¹ßÀ²ÀÌ Àû¾úÀ¸³ª Åë°èÀû À¯ÀǼºÀº ¾ø¾ú´Ù(50 vs. 26%).
°á·ÐÀûÀ¸·Î Àç¹ß¼º º¹¸·¿° ¹ß»ý½Ã vancomycinÀ» Åõ¿©ÇÑ ¹æ¹ý°ú Áõ»ó ¼Ò½Ç ÈÄ 10ÀÏ ÀÌ»ó
Áö¼ÓÀûÀ¸·Î Ç×»ýÁ¦¸¦ Åõ¿©ÇÑ ¹æ¹ýÀÌ º¸´Ù ´õ È¿°úÀûÀ̾úÀ¸¸ç, Ç×»ýÁ¦ Ä¡·á¿¡ ¹ÝÀÀÀÌ ¾ø´Â
Àç¹ß¼º º¹¸·¿°ÀÇ °æ¿ì µµ°ü Á¦°Å ÈÄ ÀûÀýÇÑ Ç×»ýÁ¦ Åõ¿© ¹× µµ°ü Àç»ðÀÔÀ» ÀÌ¿ëÇÑ Ä¡·á¹æ¹ý
ÀÌ ÇÊ¿äÇÒ °ÍÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Relapsing peritonitis are major limitation of CAPD, a common reason for
discontinuation of this form of therapy. Inappropriate treatnent of previous peritonitis
often leads to relapsing peritonitis, especially in patients with catheter-related infections.
Although a multitude of therapeutic approaches have been tried, there is a controversy
over the optimal antimicrobial treatment. The purposes of this study were: 1) to analyze
the causative pathogen; 2) to determine the appropriate treatment regimen and duration;
and 3) to evaluate the role of catheter replacement in recurrent peritonitis. Follow-up
data were obtained in 43 CAPD patients who experienced 104 episodes of reucrrent
peritonitis.
1) Among 104 episodes of recurrent peritonitis, 70(67%) were culture-positive. The
distribution of isolates was as follows : coagulase negative Staphylococci, 39 (38%);
Enterococcus, 9 (9%); Staphylococcus aureus, 8 (8%); Pseudomonas, 4 (4%); Serratia, 4
(4%); Xanthomonas, 3 (3%); Klebsiella, 2 (2%); and fungus, 1 (1%).
2) Peritonitis recurred in 46 (50%) and did not recur in the other 46 (50%) of the 92
catheter-maintained peritonitis. After catheters were removed in 12 patients, new
catheters were inserted in 3 patients without any more peritonitis.
3) There was no significant difference of recurrence between Gram-positive and
Gram-negative Peritonitis (56 vs. 50%).
4) Five (29%) of 17 peritonitis treated with van-comycin and amikacin, and 22 (73%)
of 30 peritonitis treated with cefazolin and tobramycin experienced recurrence. Compared
with cefazolin, initial therapy with vancomycin decreased the recurrence rate (p<0.05).
5) In Gram-positive and Gram-negative peritonitis, there was no reduction of
recurrence in peritonitis treated for more than 2 weeks (63 vs.51%, 40 vs. 60%). In
coagulase negative Staphylococcal peritonitis, treatment for more than 2 weeks reduced
the recurrence without statistical significance (59 vs. 30%, p=0.10).
6) In Gram-positive and Gram-negative peritonitis, there was no reduction of
recurrence in peritonitis treated for more than 10 days after resolution(59 vs. 53%, 40
vs. 69%). In coagulate negative Staphylococcal peritonitis, treatment more than 10 days
after resolution reduced the recurrence without statistical significance (50 vs. 26%,
p=0.08).
In conclusion, treatment with vancomycin and a longer treatment duration seem to be
beneficial in relapsing CAPD peritonitis. Moreover, removal and replacement of catheter
should be considered in cases unresponsive to antibiotic treatment.

Å°¿öµå

CAPD; Recurrent peritonitis; Treatment;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS